Oxford, United Kingdom – 10th May 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, is pleased to confirm that it will be presenting and attending a number of upcoming conferences, as detailed below.

• BioEquity Europe 2024, May 12-14, San Sebastian – Rosamond Deegan, CEO of OMass; Ali Jazayeri, CSO of OMass
  • Corporate presentation on May 13 at 12:15

• Endocrine Society (ENDO) Annual Meeting 2024, June 1-4, Boston

• I-DSD Symposium 2024, June 26-28, Stockholm – Miguel Silva, Senior Strategy Director

Rosamond Deegan, CEO of OMass of OMass said: “We have made great strides across our portfolio, including our MC2 antagonist, and are excited to share this progress at various business and scientific meetings.”

If you would like to meet with any of the OMass team during these events or at any other time, please contact miguel.silva@omass.com.

-ENDS-

For further information, please contact:

About OMass Therapeutics

OMass Therapeutics is a biotechnology company discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. This allows OMass to interrogate not just the target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs.

Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

To learn more, please visit www.omass.com. Follow us on LinkedIn and Twitter.